ATED Therapeutics Ltd. — SEC Form D Filing

ATED Therapeutics Ltd. filed an SEC Form D on April 2, 2026, reporting $670K raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
April 2, 2026
Amount reported
$670K
Round stage
Seed
Industry
Health Care
Website
https://www.atedtherapeutics.org/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: ISRAEL

Problem

There is a need for rapid and accurate diagnostics for Parkinson's Disease, especially in its earliest stages.

Solution

ATED Therapeutics has developed a non-invasive blood-based diagnostic test that detects Parkinson's Disease and measures the effectiveness of deep brain stimulation.

Why now

With over 10 million cases worldwide and a significant increase in diagnoses, there is an urgent demand for better diagnostic solutions for Parkinson's Disease.

Verdict

Investors backed ATED Therapeutics because the urgent need for accurate diagnostics in Parkinson's Disease created a compelling narrative, not because of a robust and proven business model. This investment implied a bet on the company's potential to establish itself in a rapidly evolving health tech space, yet offered limited upside given the crowded diagnostics market and the uncertainty surrounding regulatory approvals. The anticipation of future demand for non-invasive solutions provided a semblance of durability, but investor confidence hinges on execution and clinical validation.

Source: SEC EDGAR Form D filing